Literature DB >> 30382731

Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys.

Lisa R Gerak1, Gregory T Collins1, David R Maguire1, Charles P France1.   

Abstract

Drug abuse remains a serious public health issue, underscoring the need for additional treatment options. Agonists at serotonin (5-HT)2C receptors, particularly lorcaserin, are being considered as pharmacotherapies for abuse of a variety of drugs, including cocaine and opioids. The current study compared the capacity of lorcaserin to attenuate reinstatement of extinguished responding previously maintained by either cocaine or an opioid; this type of procedure is thought to model relapse, an important aspect of drug abuse. Six rhesus monkeys responded under a fixed-ratio schedule for cocaine (0.032 mg/kg/infusion) or remifentanil (0.00032 mg/kg/infusion). Reinstatement of extinguished responding was examined following administration of noncontingent infusions of cocaine (0.32 mg/kg) or heroin (0.0032-0.1 mg/kg) combined with response-contingent presentations of the drug-associated stimuli, or heroin alone without presentation of drug-associated stimuli. When combined with drug-associated stimuli, cocaine and heroin increased extinguished responding. On average, monkeys emitted fewer reinstated responses following 0.32 mg/kg cocaine, compared with the number of responses emitted when cocaine was available for self-administration or when extinguished responding was reinstated by 0.032 mg/kg heroin. When drug-associated stimuli were not presented, heroin did not increase responding. Lorcaserin dose dependently attenuated reinstated responding, and its potency was similar regardless of whether cocaine or heroin was given before reinstatement sessions. The generality of this effect of lorcaserin across pharmacological classes of abused drugs might make it particularly useful for reducing relapse-related behaviors in polydrug abusers. (PsycINFO Database Record (c) 2019 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30382731      PMCID: PMC6355344          DOI: 10.1037/pha0000234

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  30 in total

1.  Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress.

Authors:  A D Lê; C X Poulos; S Harding; J Watchus; W Juzytsch; Y Shaham
Journal:  Neuropsychopharmacology       Date:  1999-09       Impact factor: 7.853

2.  The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control.

Authors:  Guy A Higgins; Leo B Silenieks; Anne Rossmann; Zoe Rizos; Kevin Noble; Ashlie D Soko; Paul J Fletcher
Journal:  Neuropsychopharmacology       Date:  2011-12-21       Impact factor: 7.853

3.  The 5-HT(2C) receptor agonist lorcaserin reduces cocaine self-administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity.

Authors:  Colin Harvey-Lewis; Zhaoxia Li; Guy A Higgins; Paul J Fletcher
Journal:  Neuropharmacology       Date:  2015-09-30       Impact factor: 5.250

4.  Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users.

Authors:  M J Shram; K A Schoedel; C Bartlett; R L Shazer; C M Anderson; E M Sellers
Journal:  Clin Pharmacol Ther       Date:  2011-03-16       Impact factor: 6.875

5.  Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats.

Authors:  Harshini Neelakantan; Erica D Holliday; Robert G Fox; Sonja J Stutz; Sandra D Comer; Margaret Haney; Noelle C Anastasio; F Gerard Moeller; Kathryn A Cunningham
Journal:  ACS Chem Neurosci       Date:  2017-02-13       Impact factor: 4.418

6.  Choice between delayed food and immediate opioids in rats: treatment effects and individual differences.

Authors:  Leigh V Panlilio; Maria E Secci; Charles W Schindler; Charles W Bradberry
Journal:  Psychopharmacology (Berl)       Date:  2017-09-04       Impact factor: 4.530

7.  Reinstatement of cocaine-reinforced responding in the rat.

Authors:  H de Wit; J Stewart
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

8.  Lorcaserin Reduces the Discriminative Stimulus and Reinforcing Effects of Cocaine in Rhesus Monkeys.

Authors:  Gregory T Collins; Lisa R Gerak; Martin A Javors; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2015-11-03       Impact factor: 4.030

9.  Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.

Authors:  William J Thomsen; Andrew J Grottick; Frederique Menzaghi; Hazel Reyes-Saldana; Stephen Espitia; Diane Yuskin; Kevin Whelan; Michael Martin; Michael Morgan; Weichao Chen; Hussien Al-Shamma; Brian Smith; Derek Chalmers; Dominic Behan
Journal:  J Pharmacol Exp Ther       Date:  2008-02-05       Impact factor: 4.030

10.  Changes in opiate and stimulant use through 10 years: The role of contextual factors, mental health disorders and psychosocial factors in a prospective SUD treatment cohort study.

Authors:  Grethe Lauritzen; Trond Nordfjærn
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

View more
  14 in total

1.  Lorcaserin maintenance fails to attenuate heroin vs. food choice in rhesus monkeys.

Authors:  E Andrew Townsend; S Stevens Negus; Justin L Poklis; Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2020-01-17       Impact factor: 4.492

2.  Effects of the synthetic cannabinoid receptor agonist JWH-018 on abuse-related effects of opioids in rhesus monkeys.

Authors:  Lisa R Gerak; Peter F Weed; David R Maguire; Charles P France
Journal:  Drug Alcohol Depend       Date:  2019-06-29       Impact factor: 4.492

3.  OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention.

Authors:  David R Maguire; Lisa R Gerak; Gerta Cami-Kobeci; Stephen M Husbands; Charles P France; Barbara Belli; Peter Flynn
Journal:  J Pharmacol Exp Ther       Date:  2019-11-20       Impact factor: 4.030

4.  OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects.

Authors:  Lisa R Gerak; David R Maguire; Gerta Cami-Kobeci; Keith M Olson; John R Traynor; Stephen M Husbands; Charles P France; Lisette Acevedo; Barbara Belli; Peter Flynn
Journal:  Behav Pharmacol       Date:  2022-08-03       Impact factor: 2.277

5.  Effects of buprenorphine/lorcaserin mixtures on preference for heroin, cocaine, or saline over food using a concurrent choice procedure in rhesus monkeys.

Authors:  Lisa R Gerak; Charles P France
Journal:  Drug Alcohol Depend       Date:  2021-08-28       Impact factor: 4.852

Review 6.  Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.

Authors:  Reda M Chalhoub; Peter W Kalivas
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

Review 7.  Learning from lorcaserin: lessons from the negative clinical trial of lorcaserin to treat cocaine use disorder.

Authors:  S Stevens Negus; Matthew L Banks
Journal:  Neuropsychopharmacology       Date:  2020-08-24       Impact factor: 7.853

8.  Adjunctive effect of the serotonin 5-HT2C receptor agonist lorcaserin on opioid-induced antinociception in mice.

Authors:  Salvador Sierra; Kumiko M Lippold; David L Stevens; Justin L Poklis; William L Dewey; Javier González-Maeso
Journal:  Neuropharmacology       Date:  2020-01-24       Impact factor: 5.273

Review 9.  Converging vulnerability factors for compulsive food and drug use.

Authors:  Katherine M Serafine; Laura E O'Dell; Eric P Zorrilla
Journal:  Neuropharmacology       Date:  2021-04-20       Impact factor: 5.273

10.  Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration.

Authors:  Noelle C Anastasio; Dennis J Sholler; Robert G Fox; Sonja J Stutz; Christina R Merritt; James M Bjork; F Gerard Moeller; Kathryn A Cunningham
Journal:  Neuropharmacology       Date:  2020-02-14       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.